Codexis completes biocatalyst tech transfer to Teva
Codexis has completed technology transfer of custom biocatalysts to Teva, leading to their use in pilot plants and commercial scale production.
Teva and Codexis first entered into an agreement in 2009. Codexis has developed biocatalysts to cut pharmaceutical manufacturing time and costs in two Teva pilot production lines and one full scale commercial plant.
"We are developing custom biocatalytic manufacturing processes for four Teva products, and the transfer to pilot and commercial manufacturing is important recognition of the cost savings and value-added technology”, said Joseph Sarret, chief business officer at Codexis.
